Previous 10 | Next 10 |
STAMFORD, Conn., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announ...
Image source: The Motley Fool. Cara Therapeutics Inc (NASDAQ: CARA) Q2 2020 Earnings Call Aug 10, 2020 , 6:30 p.m. ET Operator Continue reading
Cara Therapeutics, Inc. (CARA) Q2 2020 Earnings Conference Call August 10, 2020 04:30 PM ET Company Participants Jack Hildick-Smith - Stern IR Derek Chalmers - President and CEO Rick Makara - VP and Head, Accounting Conference Call Participants Chris Howerton - Jefferies ...
Cara Therapeutics (NASDAQ: CARA ) : Q2 GAAP EPS of -$0.54 beats by $0.12 . Revenue of $5.63M (+8.3% Y/Y) beats by $0.57M . Press Release More news on: Cara Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,
– Conference call today at 4:30 p.m. ET – STAMFORD, Conn., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively t...
STAMFORD, Conn., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, tod...
STAMFORD, Conn., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today ann...
Will These Pot Stocks Survive The Cannabis Industry In the Long Term As we search the cannabis industry for marijuana stocks to watch, finding the right ones can be difficult. Which pot stock has all the right financials and future plans on tap? Which pot stock will be able to survive with...
There's a number of upcoming catalysts in the liver disease treatment space, prompting Needham to update its takes on drugmakers targeting the diseases. More news on: Intercept Pharmaceuticals, Inc., Albireo Pharma, Inc., Mirum Pharmaceuticals, Inc., Healthcare stocks news, Notable Calls ...
STAMFORD, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today an...
News, Short Squeeze, Breakout and More Instantly...
Cara Therapeutics Inc. Company Name:
CARA Stock Symbol:
NASDAQ Market:
Cara Therapeutics Inc. Website:
– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Onset of action seen at Week 1 and sustained through Week 8 – – Statistical significance achieve...
KORSUVA™ (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation Kapruvia ® (difelikefalin) approved by European Commission for the treatment of moderate-to-severe pruritus associated with chronic kidney disease...
STAMFORD, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President an...